Abstract
Clinical heterogeneity is common in Mendelian disease, but small sample sizes make it difficult to identify specific contributing factors. However, if a rare disease represents the severely affected extreme of a spectrum of phenotypic variation, then modifier effects may be apparent within a larger subset of the population. Analyses that take advantage of this full spectrum could have substantially increased power. To test this, we developed cryptic phenotype analysis (CPA), a model-based approach that uses symptom data to infer latent quantitative traits that capture disease-related phenotypic variability. By applying this approach to 50 Mendelian diseases in two large cohorts of patients, we found that these quantitative traits reliably captured disease severity. We then conducted genome-wide association analyses for five of the inferred cryptic phenotypes, uncovering common variation that was predictive of Mendelian disease-related diagnoses and outcomes. Overall, this study highlights the utility of computationally derived phenotypes and biobank-scale cohorts for investigating the complex genetic architecture of Mendelian diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Stimulating Access to Research in Residency (StARR) program at UCSF (NHLBI grant 5R38HL143581-03; PI Alison Huang), which provided funding for the first author and data access. The first author was also supported by the UCSF Pediatrics and Medical Genetics Residency Programs.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used de-identified human genetic and clinical information (UCSF IRB #: 19-29458). It qualified for Exempt status. Access to the UK Biobank was approved through their standard application process (Application 53312).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The clinical and genetic datasets used in the analyses presented in this manuscript cannot be shared directly with third parties, as both have specific provisions against open data sharing outside of their usual application processes. Information regarding third party access to the UCSF De-Identified Clinical Data Warehouse can be found through UCSF Data Resources: https://data.ucsf.edu/cdrp/research, and the application process for access to the UK Biobank is outlined on their website: https://www.ukbiobank.ac.uk/register-apply. Datasets that were generated to conduct the analyses described in this manuscript are provided as Supplementary Data Files 1-10.
